Experimental Transfusion Medicine Dresden

Publications

 
2017

Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, Seifried E, Wels WS, Tonn T: Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother, 2017

Mitroulis I, Chen LS, Singh RP, Kourtzelis I, Economopoulou M, Kajikawa T, Troullinaki M, Ziogas A, Ruppova K, Hosur K, Maekawa T, Wang B, Subramanian P, Tonn T, Verginis P, von Bonin M, Wobus M, Bornhäuser M, Grinenko T, Di Scala M, Hidalgo A, Wielockx B, Hajishengallis G, Chavakis T: Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. J Clin Invest, 2017

Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kühn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stölzel F, Tonn T, Stevanovic S, Rammensee HG, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhäuser M, Schetelig J, Schmitz M: Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells. Haematologica, 2017

Bonnas C, Wüstefeld L, Winkler D, Kronstein-Wiedemann R, Dere E, Specht K, Boxberg M, Tonn T, Ehrenreich H, Stadler H, Sillaber I: EV-3, an endogenous human erythropoietin isoform with distinct functional relevance. Sci Rep, 2017

Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS: Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol, 2017

Arlt N, Rothe R, Juretzek T, Peltroche H, Tonn T, Moog R: Detection of the relatively slow-growing Propionibacterium acnes in seven matrices of blood components and advanced therapeutical medicinal products. Transfus Apher Sci, 2017

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU: Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia, 2017

Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS: Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy, 2017

Tunger A, Wehner R, von Bonin M, Kühn D, Heidenreich F, Matko S, Nauerth M, Rücker-Braun E, Dietz S, Link CS, Eugster A, Odendahl M, Busch DH, Tonn T, Bonifacio E, Germeroth L, Schetelig J, Bachmann MP, Bornhäuser M, Schmitz M: Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology. Leuk Lymphoma, 2017

2016

Rahmig S, Kronstein-Wiedemann R, Fohgrub J, Kronstein N, Nevmerzhitskaya A, Bornhäuser M, Gassmann M, Platz A, Ordemann R, Tonn T, Waskow C: Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice. Stem Cell Reports, 2016

Suck G, Linn YC, Tonn T: Natural Killer Cells for Therapy of Leukemia. Transfus Med Hemother, 2016

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T: CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med, 2016

Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C: Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother, 2016

Abdelbaset-Ismail A, Borkowska S, Janowska-Wieczorek A, Tonn T, Rodriguez C, Moniuszko M, Bolkun L, Koloczko J, Eljaszewicz A, Ratajczak J, Ratajczak MZ, Kucia M: Novel evidence that pituitary gonadotropins directly stimulate human leukemic cells-studies of myeloid cell lines and primary patient AML and CML cells. Oncotarget, 2016

Nowotny J, Farack J, Vater C, Johnsen M, Gelinsky M, Tonn T, Kasten P: Translation of cell therapy into clinical practice: validation of an application procedure for bone marrow progenitor cells and platelet rich plasma. J Appl Biomater Funct Mater, 2016

Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T: NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother, 2016

Schüssler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O’Donovan M, Hill J, Hystad M, Jovinge S, Kyselovič J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P: Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. Eur J Heart Fail, 2016

 2015

Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, O’Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BW, Wauben M, Andaloussi SE, Théry C, Rohde E, Giebel B: Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. J Extracell Vesicles, 2015

Zhang C, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS: ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J Natl Cancer Inst, 2015

Burkhardt T, Dimanski B, Karl R, Sievert U, Karl A, Hubler C, Tonn T, Sopvinik I, Ertl H, and R Moog: Donor vigilance data of a blood transfusion service: A multicenter analysis. Transfus Apher Sci, 2015.

Toma M, Wehner R, Kloss A, Hubner L, Fodelianaki G, Erdmann K, Fussel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schakel K, Bornhauser M, Bachmann MP, Wirth MP, Baretton G, and M Schmitz: Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Oncoimmunology, 2015.

Muller MM,Geisen C, Zacharowski K, Tonn T, and E Seifried: Transfusion of Packed Red Cells. Dtsch Arztebl Int, 2015.

Kraft D, Ritter S, Durante M, Seifried E, Fournier C, and T Tonn: Transmission of clonal chromosomal abnormalities in human hematopoietic stem and progenitor cells surviving radiation exposure. Mutat Res, 2015.

Gouveia de Andrade AV, Bertolino G, Riewaldt J, Bieback K, Karbanová J, Odendahl M, Bornhäuser M, Schmitz M, Corbeil D, and T Tonn: Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev, 2015.

Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, and WS Wels: Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther, 2015.

Wuchter P, Bieback K, Schrezenmeier H, Bornhäuser M, Müller LP, Bönig H, Wagner W, Meisel R, Pavel P, Tonn T, Lang P, Müller I, Renner M, Malcherek G, Saffrich R, Buss EC, Horn P, Rojewski M, Schmitt A, Ho AD, Sanzenbacher R, and M Schmitt: Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy, 2015.

2014

Odendahl M, Grigoleit GU, Bönig H, Neuenhahn M, Albrecht J, Anderl F, Germeroth L, Schmitz M, Bornhäuser M, Einsele H, Seifried E, Busch DH, and T Tonn: Clinical-scale isolation of ‘minimally manipulated’ cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy, 2014.

Preti RA, Chan WS, Kurtzberg J, Dornsife RE, Wallace PK, Furlage R, Lin A, Omana-Zapata I, Bonig H, and T Tonn: Multi-site evaluation of the BD Stem Cell Enumeration Kit for CD34(+) cell enumeration on the BD FACSCanto II and BD FACSCalibur flow cytometers. Cytotherapy, 2014.

Stemberger C, Graef P, Odendahl M, Albrecht J, Dössinger G, Anderl F, Buchholz VR, Gasteiger G, Schiemann M, Grigoleit GU, Schuster FR, Borkhardt A, Versluys B, Tonn T, Seifried E, Einsele H, Germeroth L, Busch DH, and M Neuenhahn: Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood, 2014.

Assmus B, Leistner DM, Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Sedding D, Yu J, Corti R, Mathey DG, Barth C, Mayer-Wehrstein C, Burck I, Sueselbeck T, Dill T, Hamm CW, Tonn T, Dimmeler S, and AM Zeiher; REPAIR-AMI Study Group: Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. Eur Heart J, 2014.

de Andrade AV, Riewaldt J, Wehner R, Schmitz M, Odendahl M, Bornhäuser M, and T Tonn: Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells. J Cell Mol Med, 2014.

 2013

Tonn T, Schwabe D, Klingemann H, Becker S, Esser R, Koehl U, Suttorp D, Seifried E, Ottmann OG, and G Bug: Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 2013.

Assmus B, Walter DH, Seeger FH, Leistner DM, Steiner J, Ziegler I, Lutz A, Khaled W, Klotsche J, Tonn T, Dimmeler S, and AM Zeiher: Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA, 2013.

Jähnisch H, Wehner R, Tunger A, Kunze A, Oehrl S, Schäkel K, Rohayem J, Bornhäuser M, Tonn T, Bachmann M, and M. Schmitz: TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. Cancer Lett, 2013.

Gutensohn K, Odendahl M, Kersten JF, and T Tonn: Validation of cord blood split products prepared by an automated method. Transfus Med, 2013.

Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, Tichelli A, Schwabe D, and U Koehl: Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant, 2013.

 2012

Tonn T, Schwabe D, Klingemann H, Becker S, Esser R, Koehl U, Suttorp D, Seifried E, Ottmann OG, and G Bug: Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 2013.

Assmus B, Walter DH, Seeger FH, Leistner DM, Steiner J, Ziegler I, Lutz A, Khaled W, Klotsche J, Tonn T, Dimmeler S, and AM Zeiher: Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA, 2013.

Jähnisch H, Wehner R, Tunger A, Kunze A, Oehrl S, Schäkel K, Rohayem J, Bornhäuser M, Tonn T, Bachmann M, and M. Schmitz: TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. Cancer Lett, 2013.

Gutensohn K, Odendahl M, Kersten JF, and T Tonn: Validation of cord blood split products prepared by an automated method. Transfus Med, 2013.

Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, Tichelli A, Schwabe D, and U Koehl: Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant, 2013.

2011

Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schlüter M, Tonn T, Seeger F, Dimmeler S, Lindhoff-Last E, and AM Zeiher AM (PROVASA Investigators): Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv, 2011.

Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth M, Greiner J, Michel D, Mertens T, Rojewski M, Marx M, von Harsdorf S, Döhner H, Seifried E, Bunjes D, and M Schmitt: Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion, 2011.

Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, and T Tonn: Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit. Cytotherapy, 2011.

Schüttrumpf J, Milanov P, Abriss D, Roth S, Tonn T, and E Seifried: Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX. Hum Gene Ther, 2011.

2010

Tonn T*, Assmus B*, Seeger FH*, Yoon CH, Leistner D, Klotsche J, Schächinger V, Seifried E, Zeiher AM, and S Dimmeler: Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol, 2010. *contributed equally

Kuci S, Kuci Z, Kreyenbeg H, Deak E, Pütsch K, Huenecke S, Amara C, Koller S, Rettinger E, Grez M, Koehl U, Latifi-Pupovci H, Henschler R, Tonn T, von Laer D, Klingebiel T, and P Bader: CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica, 2010.

2009

Heinz S, Schüttrumpf J, Simpson JC, Pepperkok R, Nicolaes GA, Abriss D, Milanov P, Roth S, Seifried E, and T Tonn: Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII. Thromb Haemost, 2009.

Schmidt M, Spengler HP, Lambrecht B, Hourfar MK, Seifried E, and T Tonn: A new one-platform flow cytometric method for residual cell counting in platelet concentrates. Transfusion, 2009.

Ramos-Lopez E, Scholten F, Aminkeng F, Wild C, Kalhes H, Seidl C, Tonn T, Van der Auwera B, and K Badenhoop: Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA-C1 ligand binding. Tissue Antigens, 2009.

Weber G, Karbach J, Kuçi S, Kreyenberg H, Willasch A, Koscielniak E, Tonn T, Klingebiel T, Wels WS, Jäger E, and P Bader: WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia, 2009.

Kapp M, Stevanović S, Fick K, Tan SM, Loeffler J, Opitz A, Tonn T, Stuhler G, Einsele H, and GU Grigoleit: CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant, 2009.

Tramsen L, Koehl U, Tonn T, Latgé JP, Schuster FR, Borkhardt A, Uharek L, Quaritsch R, Beck O, Seifried E, Klingebiel T, and T Lehrnbecher: Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant, 2009.

Becker D, Elsässer T, Tonn T, Seifried E, Durante M, Ritter S, Fournier C: Response of human hematopoietic stem and progenitor cells to energetic carbon ions. Int J Radiat Biol, 2009

Fischer-Rasokat U, Assmus B, Seeger FH, Honold J, Leistner D, Fichtlscherer S, Schächinger V, Tonn T, Martin H, Dimmeler S, Zeiher AM: A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail, 2009

Schächinger V, Assmus B, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Yu J, Corti R, Mathey DG, Hamm CW, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI investigators: Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail, 2009

Reesink HW, Panzer S, Dettke M, Gabriel C, Lambermont M, Deneys V, Sondag D, Dickmeiss E, Fischer-Nielsen A, Korhonen M, Krusius T, Ali A, Tiberghien P, Schrezenmeier H, Tonn T, Seifried E, Klüter H, Politis C, Stavropoulou-Gioka A, Parara M, Flesland O, Nascimento F, Balint B, Marin P, Bart T, Chen FE, Pamphilon DH: New cellular therapies: is there a role for transfusion services? Vox Sang, 2009

Hermann FG, Martinius H, Egelhofer M, Giroglou T, Tonn T, Roth SD, Zahn R, Schult-Dietrich P, Alexandrov A, Dietrich U, Baum C, von Laer D: Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides. Hum Gene Ther, 2009

Rupp S, Bauer J, Tonn T, Schächinger V, Dimmeler S, Zeiher AM, Schranz D: Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr Transplant, 2009

2008

Tonn T and D Barz: MSC – a Multipotent Stromal Cell in Search of Clinical Application. Transfus Med Hemother, 2008.

Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, and WS Wels: Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother, 2008.

Schüttrumpf J, Milanov P, Roth S, Seifried E, Tonn T: [Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice]. Hamostaseologie, 2008

Picanço-Castro V, Fontes AM, Heinz S, Tonn T, Covas DT: The chimeric cytokine Hyper-IL-6 enhances the efficiency of lentiviral gene transfer in hepatocytes both in vitro and in vivo. Biotechnol Lett, 2008

2007

Seeger FH, Tonn T, Krzossok N, Zeiher AM, and S Dimmeler: Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J, 2007.

Picanço V, Heinz S, Bott D, Behrmann M, Covas DT, Seifried E, and T Tonn: Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter. Cytotherapy, 2007.

Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, Ottmann OG: Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis.Transfusion, 2007

Erbs S, Linke A, Schächinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, Zeiher AM, Schuler G: Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation, 2007

Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, Seifried E, Schächinger V, Dimmeler S, Zeiher AM; TOPCARE-CHD Registry: Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res, 2007

2006

Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, and AM Zeiher: Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med, 2006.

Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, and AM Zeiher (REPAIR-AMI Investigators): Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med, 2006.

Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J, 2006

Schmidt M, Hourfar MK, Nicol SB, Wahl A, Heck J, Weis C, Tonn T, Spengler HP, Montag T, Seifried E, Roth WK.: A comparison of three rapid bacterial detection methods under simulated real-life conditions.Transfusion, 2006

Schächinger V, Tonn T, Dimmeler S, Zeiher AM: Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med, 2006

2005

Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, and T Tonn: Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol, 2005.

Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, Sörensen J, Grüttner HP, Bader P, Seifried E, Martin H, Lang P, Passweg JR, Klingebiel T, Schwabe D: Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr, 2005

2004

Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D: IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis, 2004

Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.Thromb Haemost, 2004

Wels W, Biburger M, Müller T, Dälken B, Giesübel U, Tonn T, Uherek C: Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol Immunother, 2004

2003

Herder C, Tonn T, Oostendorp R, Becker S, Keller U, Peschel C, Grez M, Seifried E: Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol, 2003

Richter-Hintz D, Their R, Steinwachs S, Kronenberg S, Fritsche E, Sachs B, Wulferink M, Tonn T, Esser C: Allelic variants of drug metabolizing enzymes as risk factors in psoriasis. J Invest Dermatol, 2003

Becker S, Tonn T, Füssel T, Uhrberg M, Bogdanow M, Seifried E, Seidl C: Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. Hum Immunol, 2003

2002

Tonn T, Herder C, Becker S, Seifried E, Grez M: Generation and characterization of human hematopoietic cell lines expressing factor VIII. J Hematother Stem Cell Res, 2002

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W: Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood,  2002

2001

Tonn T, Becker S, Esser R, Schwabe D, Seifried E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res, 2001

1999

Hennemann B, Tam YK, Tonn T, Klingemann HG: Expression of SCM-1alpha/lymphotactin and SCM-1beta in natural killer cells is upregulated by IL-2 and IL-12. DNA Cell Biol, 1999

Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG: Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther, 1999

1997

Tonn T, Westrup D, Seidl C, Kirchmaier CM, Seifried E: Sensitive determination of the RhD genotype in mixed samples using fluorescence-based polymerase chain reaction. Vox Sang, 1997

 1996

Tonn T, Esser C, Schneider EM, Steinmann-Steiner-Haldenstätt W, Gleichmann E: Persistence of decreased T-helper cell function in industrial workers 20 years after exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Environ Health Perspect, 1996

 1995

Goebel C, Kubicka-Muranyi M, Tonn T, Gonzalez J, Gleichmann E: Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes. Arch Toxicol, 1995

 1994

Tonn T, Goebel C, Wilhelm M, Gleichmann E: Gold kinetics under long-term treatment with gold(I) disodium thiomalate: a comparison in three different mouse strains. Br J Rheumatol, 1994